GSK, Genmab fail to get NICE nod for leukemia drug

06/23/2010 | Reuters

The U.K.'s National Institute for Health and Clinical Excellence decided not to endorse GlaxoSmithKline and Genmab's leukemia drug Arzerra, citing lack of evidence on the drug's effectiveness compared with standard treatment. GSK recently failed to gain NICE recommendation for cancer medicine Tyverb and platelet drug Revolade.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR